A high expression of Eno2 has been reported in breast cancer, acute lymphoblastic leukemia, small cell lung cancer, neuroblastoma, melanoma, retinoblastoma, seminoma, dysgerminoma, malignant phaeochromocytoma, pancreatic ductal adenocarcinoma, prostate cancer, liver cancer, cervical cancer, esophageal cancer, kidney cancer, sarcoma, colorectal cancer, and head and neck squamous cell carcinoma [49,50,51,52,53,54,55,56]. Here, ENO2 is linked to seminoma.